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ABSTRACT 
 
 
OBJECTIVE: The objectives of this selective EBM review is to determine whether or not 
Autologous Chondrocyte Implantation is more effective than microfracture in the repair 
of articular knee defects. 
 
STUDY DESIGN: Review of three English language primary studies published in 2009 
and 2010. 
 
DATA SOURCES: Randomized controlled trials comparing Autologous Chondrocyte 
Implantation and Microfracture found using PubMed, MedLine and Cochrane Database.  
 
OUTCOMES MEASURED: Clinical outcome measured by the Knee Injury and 
Osteoarthritis Outcome Score (KOOS). The primary measure of outcome was evaluated 
using the KOOS questionnaire with subdomains of ADL’s, pain, symptoms, stiffness and 
quality of life. KOOS data was compared between treatment groups for patients with 
symptom onset less than 2 years vs  more than 2 years and less or more than 3 years. 
Serial MRI scans were scored using Magnetic resonance Observation of Cartilage Repair 
Tissue (MOCART) system. A rehabilitation protocol was implemented where 
components were evaluated pre surgery and at 6, 9, 12 and 24 months post surgery. 
Patients are followed up 8-12, 22-26, 50-54 weeks post operatively for efficacy and 
safety evaluations.  
 
RESULTS: Three randomized controlled trials were included in this review. The study 
by Basad indicated ACI as having significantly more effective outcomes over 2 years 
compared to microfracture. Saris’ study provided similar conclusions, offering improved 
outcomes with ACI after 36 months. However, Van Assche’s study had similar overall 
functional outcomes for both ACI and MF.  
 
CONCLUSIONS: Based on findings upon analysis of three RCT’s, Autologous 
chondrocyte implantation provides significant improvement in articular knee defects 
allowing improved function, mobilitiy and activity as compared to that of microfracture.  
 
KEY WORDS: Autologous chondrocyte implantation, microfracture 
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Introduction: 
ACI is an advanced cell based technique for treatment of cartilage defects. Damage to 
the articular cartilage limits activity level as well as the ability for reparation and 
restoration of the knee. Intact articular cartilage is needed for normal joint movement and 
decreased friction through range of motion. The first stage of autologous chondrocyte 
implantation begins with arthroscopic sampling of cartilage from an area of limited 
weight bearing, typically from the medial or lateral femoral condyle
1
. Chondrocytes are 
then isolated where they can then be grown in vitro for 4 to 6 weeks
2
. An area of the 
periosteum is then harvested and formed into a periosteal patch that will be sutured over 
the area of damaged cartilage
3
. A tight seal will be formed so that once the cells are 
reimplanted they will be held in place at the site of injury
3
.  The cells are then reimpanted 
into the damaged area of articular cartilage through arthrotomy. The autologous cells will 
adapt by forming new cartilage into the area of the defect
3
.  
ACI is an appropriate treatment for small tears of the cartilage. It is not to be used for 
widespread wear of the cartilage such as with arthritis
1
. The patient must have a stable 
knee without associated ligament damage, must be of healthy BMI and have failed with 
nonoperative treatments
1
. Femoral condyle injuries are very common in athletes and ACI 
can be an effective technique for repair in the field of orthopedic surgery. This is 
especially useful for patients opting out of total knee replacements. The total cost for the 
ACI procedure falls between $17,600 and $38,400
6
. A patient of ACI would have 
multiple healthcare visits yearly due to the preoperative imaging needing to visualize the 
level of damage, the 2 steps in the procedure, where 6 weeks after the cells are taken the 
patient will have them reimplanted, as well as the post op follow up imaging and physical 
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exam along with necessary physical therapy. Follow up visits vary depending on level of 
pain, range of motion and disability levels. Articular cartilage defects are often due to 
sports related trauma. Due to its avascular nature it has poor ability to repair itself. Focal 
articular cartilage defects are often the source of pain and functional issues and so early 
diagnosis is important in appropriate management
10
. Articular defects if untreated can 
lead to additional injuries including menisci and cruciate ligament injuries
10
.   
 First line treatment typically includes debridement and lavage by which 
loose articular tissue debris is removed
10
. However, such management may solely have 
short term effects. Microfracture is another technique that is frequently used. 
Subchondral bone is disrupted in an attempt to initiate stem cell migration to the site of 
the defect
10
. Conservative treatments should always primarily be used. These include 
NSAID use, steroid injections, physical therapy
11
. Patients with severe injury may 
undergo total knee replacements where prosthetic tibial, femoral and posterior patellar 
surfaces are implanted
11
.  
 ACI is an appropriate treatment for small tears of the cartilage. It is not to 
be used for widespread wear of the cartilage such as with arthritis. It is a promising new 
treatment for full thickness articular cartilage defects. ACI restores the cartilage whereas 
microfracture simply covers up the defect.  
Objective: The objective of this selective EBM review is to determine whether or not 
ACI is more effective than microfracture in the repair of articular cartilage knee injuries. 
Methods: The chosen studies were all randomized controlled trials. The populations 
included were patients with symptomatic cartilage defects of the knee. The interevention 
of Autologous Chondrocyte Implantation was compared to Microfracture. Measured 
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outcomes include level of function, range of motion, mobility, strength, stiffness and 
activity of daily life. A detailed search was completed through use of search engines 
Pubmed, MedLine, and Cochrane database. Keywords “Autologous chondrocyte 
implantation” and “Microfracture” were used in combination to search for English-
language articles. All of the resulting qualified articles were published between 2009 and 
2010 in peer reviewed journals. The patients included people between the ages of 18 and 
50 with articular knee injuries. Excluded however were people with the presence of 
inflammatory arthritis, instability of the knee joint, prior or planned meniscectomy of 
over 30% of the meniscus, BMI >30, varus or valgus deformity, osteonecrosis, 
osteoarthritis or chondrocalcinosis. For this review, selected dichotomous data were 
interpreted by using statistics including P-values, NNT, RRR and ARRR.  
Table 1 - Demographics & Characteristics of included studies 
Study 
 
Type # 
of 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion 
criteria 
W/D Intervention 
Basad, 
Ehran, 2010 
RCT 60 18-50 -Symptomatic 
cartilage defects 
-Post traumatic  
-Single isolated 
chondral defects of 
the femoral condyle 
or patella. 
The prescence of 
chronic inflammatory 
arthiritis, instability 
of the knee joint, 
prior or planned 
meniscectomy of 
over 30 % of the 
meniscus, BMI 
greater than 30, varus 
or valgus deformity, 
osteonecrosis, 
osteoarthritis or 
chondrocalcinosis. 
3 Microfracture 
Saris, Daniel, 
2009 
RCT 118 18-50 Single International 
Cartilage Repair 
Society grade III/IV 
symptomatic 
cartilage defects of 
the femoral condyles 
in a stable, well 
 
No exclusion criteria 
noted 
33 Microfracture 
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aligned knee with 
minimal additional 
injury, agreeing to 
comply with a strict 
rehabilitation 
protocol  
Van Assche, 
2009 
RCT 67 18-50 -Local cartilage 
defects  w mean size 
2.4 cm of the femoral 
condyle of the knee  
 
-Symptomatic single 
cartilage lesions of 
the femoral condyle 
between 1 and 5 cm  
 
-Agreed to actively 
participate in strict 
rehabilitation and 
follow up programs.  
 
 
No exclusion criteria 
noted 
13 Microfracture 
 
Outcomes Measured: 
Clinical outcome measured by the Knee Injury and Osteoarthritis Outcome Score 
(KOOS). The primary measure of outcome was evaluated using the KOOS questionnaire, 
a validated self reported assessment consisting of 5 separately scored subdomains: 
ADL’s, pain, symptoms, stiffness and quality of life. KOOS data was compared between 
treatment groups for patients with symptom onset less than 2 years v. more than 2 years 
and less or more than 3 years. Serial MRI scans were scored using Magnetic resonance 
Observation of Cartilage Repair Tissue (MOCART) system. MRI scans were taken 1 
week post operatively to check for delamination and graft hypertrophy. A rehabilitation 
protocol was implemented for both active knee flexion and extension range, anterior 
laxity, knee extension strength and single leg hop performance. All were evaluated pre 
surgery and at 6, 9, 12 and 24 months post surgery. Patients are followed up 8-12, 22-26, 
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50-54 weeks post operatively for efficacy and safety evaluations. Tegner scores are taken 
for activity level, Lysholm scores for pain, stability, gait and clinical symptoms. ICRS 
scores were also used.  
Results: 
Three Randomized Controlled Trials were used to compare the outcomes of 
chondral knee defects upon the use of ACI versus MF.  
Van Assche’s study used a significant level set at P<0.05 and confidence interval 
of 95 %. Active knee flexion improved for both groups, but extension and anterior laxity 
remained unchanged. Single hop performance was improved more so with MF than ACI. 
At 6 months both groups had decreased functional performance, but because it was less 
pronounced in those with MF, these patients recovered to pre-surgery levels of 
performance at 9 months. However, both groups had small yet significant outcomes 
between 12 and 24 months. Most importantly, functional recovery at 2 years is 
comparable for both groups. Patients with recent osteochondritis dissecans, advanced 
osteoarthritis, ligament instability and malalignment greater than 5 degrees were 
excluded. The Number Needed to Treat was calculated to be 4.76, therefore for every 5 
patients, 1 more patient had improved outcomes compared to the control (Table 2). 
However, the Number Needed to Harm was 16.67, so for every 17 patients 1 person 
worsened compared to the control group (Table 3) 
In Basad’s study there were no significant differences except symptom duration 
which was .3 years longer in the Microfracture group. The difference between baseline 
and 2 years post operatively for Lysholm scores for both groups were significant with a 
P<.0001. However, the ACI group was more effective over time with a P = 0.005. The 
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Lysholm score rates a patients pain, swelling, mobility, limp, locking sensation, squatting 
ability, stair climbing ability, and giving out sensation on a scale. Tegner scores were also 
monitored which measures the patients activity level. This is measured preoperatively 
and postoperatively. ACI (P < 0.0001) was also significantly more effective over time 
than MF (P=0.04). Patients with osteochondral defects were withdrawn and 3 patients 
dropped out; One without reason, one became pregnant and the other was an early 
treatment failure. Significance level was set a 5 %. The Number Needed to Treat was 100 
therefore, for every 100 people treated with ACI, 1 more patient had improved outcomes 
compared to the control group (Table 2). 
Saris’ study did not provide enough information to convert to dichotomous data 
because the outcomes measured were unable to be categorized into two mutually 
exclusive groups. The median duration of symptoms was longer for patients receiving 
ACI than MF. ACI patients symptoms lasted nearly 2 years whereas MF patients lasted 
about a year and a half. Mean improvements of ADL’s, pain, symptoms, stiffness, quality 
of life and sports were all greater in the ACI group. At 36 months, more patients 
responded to ACI for KOOS responder analysis. KOOS represents the Knee Injury and 
Osteoarthritis Outcome Score.  
Table 2. Efficacy of ACI in Treatment of Chondral Defects: NNT 
Study Control 
Event Rate 
(CER) 
Experimental 
Event Rate 
(EER) 
Relative 
Benefit 
Increase 
(RBI) 
Absolute 
Benefit 
Increase 
(ABI) 
Number 
Needed to 
Treat (NNT) 
Basad, 2010 .09% .1% .111% .01% 100 
Saris, 2009 N/A N/A N/A N/A N/A 
Van Assche, 
2009 
.62% .83% .339% .21% 4.76 
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Table 3. Efficacy of ACI in Treatment of Chondral Defects: NNH 
Study Control 
Event Rate 
Experimental 
Event Rate 
Relative Risk 
Increase 
Absolute 
Risk 
Increase 
Number 
Needed to 
Harm  
Van Assche, 
2009 
.82% .88% .073% .06% 16.67 
 
Saris’ study provides plentiful data on safety assessment. 67% of people receiving 
ACI treatment and 59% of MF patients experienced at least one adverse effect over the 
entire 36 months of recovery. However, these numbers decreased to 32% and 33% 
respectively from 18 months to 36 months. Majority of adverse effects were mild to 
moderate yet 25% of both ACI and MF patients experienced at least one severe adverse 
effect. More patients receiving Microfracture experienced a significant adverse effect 
than did those with ACI. Arthralgia was the most common adverse event for both groups. 
However, patients with ACI had more joint swelling, crepitus and cartilage hypertrophy. 
3 patients of the Microfracture group withdrew due to their undesirable outcomes, 
whereas no patients of ACI were discontinued for such reasons.  
Basad’s study provided no treatment related safety issues and any irritation 
experienced was eased through the use of NSAIDs. One patient in the ACI group had 
persistent pain after one year.  
The study created by Van Assche mentions a limitation in which the patients as 
well as the physical therapists were not blinded to the treatment allocation. Future studies 
could overcome this by at least blinding the assessor to the knee of injury. One could do 
so simply by keeping the knees covered during treatment.  
Discussion: 
Controversy still exists as to whether Microfracture or Autologous Chondrocyte 
Implantation is the best repair technique. Injuries they should be used for are also still 
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being investigated. Many attempts to repair damaged articular cartilage have been met 
with issues such as inability to produce hyaline cartilage, poor integration with the 
surrounding cartilage, and gradual deterioration of the repair tissue
8
. ACI was first used 
in 1987 and has been performed on more than 12,000 patients internationally
8
. Carticel is 
currently the only FDA approved technique for culturing of chondrocytes
4
. In 1997, 
Carticel received FDA approval for the repair of clinically significant, symptomatic 
cartilaginous defects of the femoral condyle caused by acute or repetitive trauma
4
. 
ACI has demonstrated significant benefits for patients in terms of diminished pain 
and improved function. This treatment however continues to be very strictly regulated. It 
is currently the most widely researched clinical cartilage repair technique. Despite the 
fact that ACI has been in clinical use for more than 15 years, the evidence for the 
outcomes is lacking. Although this may be the procedure of the future, it does still have 
downsides including the potential leakage of chondrocytes from defects, the uneven 
distribution of cells, and the risk of periosteal complications
8
. Early problems include 
periosteal graft detachment and delamination as well as late periosteal hypertrophy
8
. 
When repairing articular defects it is important to initially diagnose and correct any 
significant comorbities such as meniscus injury, ligament laxity, or malalignment of the 
tibiofemoral or patellofemoral joint
8
. Uncorrected meniscal deficiency and ligament 
laxity are a contraindication to cartilage restoration procedures. The ACI procedure is 
predominantly for lesions larger than 2 cm
8
. Over 100 payers have medical policies that 
cover Carticel, including Cigna, Prudential, and United Healthcare. Over 50% of the 43 
independent Blue Cross and Blue Shield Association members representing 25 States 
allow coverage for ACI
9
. 
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Conclusion: 
Although there is conflicting evidence in the current literature, 2 of the 3 RCT’s 
indicate improved outcomes with ACI as compared to MF. Both Saris and Basad’s 
studies demonstrated significantly better treatment in symptomatic articular defects. 
Therefore, I agree with such studies in that ACI provides improved function, mobility 
and activities of daily life moreso than with treatment with Microfracture. va 
Autologous chondrocyte implantation is used to repair defects in the articular 
cartilage. When the cartilage is injured the chondrocytes lose their ability to regenerate 
causing loss of function and often immobility. With ACI, chondrocytes are taken from 
nonweight bearing portion of the femur, sent to a lab and cultured for reimplantation. 6 
weeks later new chondrocytes are implanted into the patient at the site of the articular 
cartilage injury
1
. The 2 primary goals for an ACI rehabilitation program are adaptation 
and remodeling of the repair as well as return to function
8
. The 3 main components of the 
rehabilitation program are progressive weightbearing, restoration of range of motion, and 
enhancement of muscle control and strengthening
8
. The repair site is at its most 
vulnerable during the first 3 months after ACI
8
. At this time, it is important to avoid 
impact as well as excessive loading and shearing forces. It is difficult to assess the 
effectiveness of ACI and its long-term results however many studies are underway in 
search of answers. Research is lacking in terms of force such grafts can endure. Future 
studies should focus on the stresses necessary to disrupt or delaminate the graft. ACI 
could be the treatment of the future as it will reduce the surgical morbitidy associated 
with open arthrotomy
8
.  
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